Other Income & Expense
Interest Expense
Alnylam Pharmaceuticals Interest Expense decreased by 36.8% to $69.29M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.8%, from $58.31M to $69.29M. Over 4 years (FY 2021 to FY 2025), Interest Expense shows an upward trend with a 15.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2022
Last reportedQ4 2025
How to read this metric
Increasing interest expense may signal higher debt levels or rising interest rates, which can reduce net profitability.
Detailed definition
Interest expense represents the cost incurred by a company for borrowed funds, such as loans, bonds, or other debt instr...
Peer comparison
Highly dependent on the company's capital structure; peers with lower debt-to-equity ratios will show lower interest expenses.
Metric ID:
interest_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $33.42M | $40.27M | $36.82M | $42.36M | $42.61M | $41.08M | $29.91M | $28.96M | $30.04M | $30.89M | $31.34M | $35.25M | $33.26M | $34.38M | $38.97M | $58.31M | $40.25M | $44.40M | $109.67M | $69.29M |
| QoQ Change | — | +20.5% | -8.6% | +15.1% | +0.6% | -3.6% | -27.2% | -3.2% | +3.7% | +2.9% | +1.4% | +12.5% | -5.7% | +3.4% | +13.4% | +49.6% | -31.0% | +10.3% | +147.0% | -36.8% |
| YoY Change | — | — | — | — | +27.5% | +2.0% | -18.8% | -31.6% | -29.5% | -24.8% | +4.8% | +21.8% | +10.7% | +11.3% | +24.4% | +65.4% | +21.0% | +29.2% | +181.4% | +18.8% |
Range$28.96M – $109.67M
CAGR+16.6%
Avg YoY Growth+19.6%
Median YoY Growth+15.0%
Interest Expense at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's interest expense?
- Alnylam Pharmaceuticals (ALNY) reported interest expense of $69.29M in Q1 2026.
- How has Alnylam Pharmaceuticals's interest expense changed year-over-year?
- Alnylam Pharmaceuticals's interest expense increased by 18.8% year-over-year, from $58.31M to $69.29M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest expense has grown at a 15.3% compound annual growth rate (CAGR), from $143.02M to $252.63M.
- What does interest expense mean?
- The cost of borrowing money, paid as interest on debt.